
10mg
Retatrutide is a novel triple agonist peptide targeting GLP-1, GIP, and glucagon receptors. This multi-receptor approach has been the focus of extensive metabolic research, with studies examining its effects on glucose homeostasis, energy expenditure, and body composition in preclinical and clinical models. The 10mg formulation provides a research-grade quantity for investigative protocols.